Free Trial

Beta Bionics (NASDAQ:BBNX) Shares Up 4.7% - Time to Buy?

Beta Bionics logo with Medical background

Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) was up 4.7% during trading on Thursday . The stock traded as high as $20.02 and last traded at $20.01. Approximately 92,799 shares changed hands during mid-day trading, a decline of 81% from the average daily volume of 498,310 shares. The stock had previously closed at $19.11.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on BBNX shares. Stifel Nicolaus started coverage on Beta Bionics in a report on Monday, February 24th. They set a "buy" rating and a $25.00 price objective on the stock. Wolfe Research started coverage on Beta Bionics in a research note on Friday, May 30th. They issued an "outperform" rating and a $20.00 price target on the stock. Leerink Partnrs raised Beta Bionics to a "strong-buy" rating in a research note on Monday, February 24th. Baird R W raised Beta Bionics to a "hold" rating in a research note on Thursday, February 20th. Finally, LADENBURG THALM/SH SH assumed coverage on Beta Bionics in a research note on Thursday, February 20th. They issued a "neutral" rating and a $20.00 price target on the stock. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $23.13.

Get Our Latest Stock Analysis on BBNX

Beta Bionics Stock Down 2.1%

The company has a 50-day moving average price of $13.92.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.01).

Insider Buying and Selling at Beta Bionics

In related news, CFO Stephen Feider sold 1,497 shares of the stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $17.89, for a total value of $26,781.33. Following the completion of the transaction, the chief financial officer now directly owns 45,503 shares of the company's stock, valued at $814,048.67. This represents a 3.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 4,519 shares of company stock worth $80,845 over the last three months.

Institutional Investors Weigh In On Beta Bionics

Large investors have recently added to or reduced their stakes in the stock. Strs Ohio bought a new position in shares of Beta Bionics during the 1st quarter valued at about $29,000. Corebridge Financial Inc. acquired a new stake in Beta Bionics in the first quarter valued at approximately $79,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Beta Bionics in the first quarter valued at approximately $95,000. MetLife Investment Management LLC purchased a new position in shares of Beta Bionics in the first quarter worth $102,000. Finally, Deutsche Bank AG purchased a new position in shares of Beta Bionics in the first quarter worth $148,000.

Beta Bionics Company Profile

(Get Free Report)

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

Recommended Stories

Should You Invest $1,000 in Beta Bionics Right Now?

Before you consider Beta Bionics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beta Bionics wasn't on the list.

While Beta Bionics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines